Cytovance Biologics News and Activities

Cytovance Biologics is owned by Shenzhen Hepalink Pharma.

Shenzhen Hepalink Pharma is a company listed under the stock ticker 002399 (CN).

Shenzhen Hepalink Pharma has a direct presence in 2 countries.

They are in:

• Pharmaceuticals50%
• Biotechnology50%

View the org chart displaying its 13 main executives

Most searched biographies at Cytovance Biologics

• Ping Zhang, Chief Executive Officer
• Axel Schleyer, Chief Commercial Officer
• Eric Bell, Senior Director of Quality

Create your alert
to follow the executive moves at Cytovance Biologics.

Shenzhen Hepalink Pharma has 2,405 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).

Popular M&A news in Biotechnology

• Ona Therapeutics has just announced a $87 Million fundraising (posted on June 5 2026).
• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Carl Gordon - Director at Odyssey Therapeutics

Learn more about the Biotechnology industry

Press releases by Cytovance Biologics

Social media about Cytovance Biologics

• Cytovance Biologics on Wikipedia, Google News & Yahoo Finance
• Cytovance Biologics on LinkedIn, X (Twitter) & YouTube